Inhalation

INH1026

Issue link: https://www.e-digitaleditions.com/i/1546950

Contents of this Issue

Navigation

Page 11 of 43

Dry powder inhalers (DPIs) are engineered to safely store and efficiently deliver predefined quantities of aerosolized active pharmaceutical ingredients (APIs). Owing to differences in the mechanisms used to deaggregate and transport aerosol particles, as well as the technologies available at the time each device was conceived, DPI mouthpieces vary widely in both size and shape. 10 OctOber 2026 Inhalation Inhaler add-ons for more efficient aerosol drug delivery Development of accessories to optimize drug deposition Árpád Farkas, PhD a ; Alpár Horváth, MD b ; Aladár Czitrovszky, DSc c,d and Attila Nagy, DSc d a HUN-REN Centre for Energy Research b Bremotech Kft. c Envi-Tech Kft. d HUN-REN Wigner Research Centre for Physics Introduction Dry powder inhalers (DPIs) are engineered to safely store and efficiently deliver predefined quantities of aerosolized active pharmaceutical ingredients (APIs). Owing to differences in the mechanisms used to deaggregate and transport aerosol particles, as well as the technologies available at the time each device was conceived, DPI mouthpieces vary widely in both size and shape. eir internal geometries also differ substantially, resulting in a broad range of airflow resistances. Consequently, the characteristics of the air and particle flows emitted near the mouthpiece are influenced not only by patient-specific factors but also by device-specific design features. Because many DPIs rely on highly swirling, turbulent airflow and particle-wall collisions to detach drug particles from their carriers, the resulting flow entering the patient's mouth is often strongly perturbed, causing parti- cle trajectories to diverge and increasing unwanted deposition in the mouth and pharynx. A direct rela- tionship has been demonstrated among the surface area of the mouthpiece outlet, the turbulence inten- sity in this region and the amount of drug deposited in the upper airways [1]. Several investigators have recognized these effects and limitations and have incorporated them into efforts to develop improved inhaler designs [2-5]. In contrast, a smaller number of authors have proposed add-on solutions intended for inhalers already on the market. Among the few examples, the effect of the length of a spacer attached to the Clickhaler ® (Philips Medisize, Hudson, Wisconsin, US) on upper-airway deposition was investigated [6]. However, not only the length, but also the shape of such add-ons can be important, therefore a method for the preliminary design and performance assessment of simple diffus- ers aimed at reducing flow complexity and turbulence levels was developed [7]. Building on this concept, a straight diffuser add-on was proposed to reduce the upper-airway deposition of terbutaline sulfate emit- ted by the Turbuhaler ® (AstraZeneca, Cambridge, UK) [8]. Within the same work, the performance of this diffuser was compared with that of a spacer incorporating a buffer zone to dissipate jets emerg- ing from the mouthpiece. More recently, a device for the Accuhaler ® (GSK, London, UK) was devel- oped with the aim to externally compensate for low patient-generated airflow [9]. Despite these efforts, such add-on concepts have generally been developed for only one or a few specific inhalers and, to the best of our knowledge, none have progressed to a market- able product. e aim of this work was to design and evaluate DPI add-on components capable of manipulating inhaled airflow to reduce upper-airway deposition and enhance pulmonary drug delivery. A further objec- tive was to assess the suitability of the proposed add- ons across different inhaler types and patient groups. To this end, numerical simulations were conducted alongside experimental measurements of drug depo- sition and transmission. e performance and appli- cability of the add-ons were then evaluated based on the experimental results. Methods Development of add-ons for the Breezhaler ® (Novar- tis, Basel, Switzerland), Turbuhaler, Ellipta ® (GSK, London, UK) and NEXaler ® (Chiesi Farmaceu- tici, Parma, Italy) DPIs was the primary focus of our research. Both numerical simulations and experi- mental measurements were performed to design and test the add-ons. Design of add-ons e design of the add-on geometries was guided primarily by fluid-dynamics principles while also

Articles in this issue

view archives of Inhalation - INH1026